GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on ...

The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...

Research presented at ENDO 2025 revealed that obesity-related cancer deaths in the U.S. have tripled over the past two decades. Thirteen types of obesity-related cancers now account for 40% of all ...

AAP recommends a multimodal approach to childhood obesity, including lifestyle changes, pharmacotherapy, and bariatric surgery, emphasizing early intervention and expanded treatment access. Addressing ...

The use of GLP-1 drugs to treat obesity has cause awareness of the complex medical condition to surge. But the cost of ...

Explore how the future of obesity drugs starts in preclinical discovery, addressing global challenges and advancing treatment ...

WHO guidelines conditionally endorse long-term GLP-1 therapy for obesity, emphasizing lifestyle modifications and addressing affordability and access challenges. GLP-1 therapies are included in the ...

Share on Pinterest The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) ...

Hypothalamic obesity is a complex condition that doesn’t always respond to traditional weight loss methods. Medications, hormonal therapy, and surgery may be necessary to see results. Hypothalamic ...